AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05678634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Probabilistic learning with immediate feedback
Description: Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 500 ms following a response (button press)
Study NCT05678634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Probabilistic learning with delayed feedback
Description: Children will complete a probabilistic learning task on a computer. Each response on half of the blocks will be followed by feedback. Feedback will be provided 5000 ms following a response (button press)
Study NCT05678634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word learning task with active feedback
Description: Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names through trial and error guided by feedback. Each response will be followed by feedback either indicating that the response is correct or prompting the child to try again (i.e., to correct an error)
Study NCT05678634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Word learning task with passive feedback
Description: Children will complete a two-choice nonword learning task in which they will be tasked with learning to associate novel objects with novel nonword names. Regardless of response accuracy on each trial, each response will be followed by a visual presentation of the correct response.
Study NCT06196606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A for injection
Description: Botulinum toxin was injected into the upper esophageal sphincter of each patient
Study NCT05542758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Body HIIT Program
Description: One repetition maximums (1RM) and body weight (BW) will be recorded at prior to and at 6 weeks to tailor the program. The circuit will be completed twice during each session and the exercises will include: squats, medicine ball forward chest throws, medicine ball overhead throw, farmers walk, seated shoulder press, seated row sitting on a fitness ball, aerobic riser step-ups, foot ladder drills, and twisting medicine ball passes. The anaerobic component will be completed once during a session and on a stationary bike. The progression of exercise:rest seconds will be 20:40 for Weeks 1-4, 30:30 for Weeks 5-8, and 40:20 for Weeks 9-12. Each session will start with a 5 minute warm up and end with a 5-minute cool down. Participants will be given real time feedback about heart rate (goal range: 85-95% HRmax) and exercise movement velocity. Participants will be encouraged to surpass the velocity of the previous repetition.
Study NCT06244667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: facet median block with prilocain
Description: facet median block with prilocain
Study NCT06244667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: facet median block with lidocaine
Description: facet median block with lidocaine
Study NCT04971356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg for 1-month (immediately after PCI)
Description: Aspirin for 1-month immediately after PCI to be a part of medication treatment in the Experimental arm
Study NCT04971356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg for 6-month (immediately after PCI)
Description: Ticagrelor for 6-month immediately after PCI to be a part of medication treatment in the Experimental arm
Study NCT04971356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg for 6-month (6-month post PCI)
Description: Aspirin for 6-month at 6 months post-PCI (after the discontinuation of the 6-month Ticagrelor treatment) to be a part of medication treatment in the Experimental arm
Study NCT04971356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg for 12-month (immediately after PCI)
Description: Aspirin for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
Study NCT04971356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90mg for 12-month (immediately after PCI)
Description: Ticagrelor for 12-month immediately after PCI to be a part of medication treatment in the Reference arm
Study NCT05870423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 18 days olaparib during each cycle of PRRT
Study NCT05180461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside
Description: emodepside tablet
Study NCT05180461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo of emodepside
Description: emodepside matching placebo tablet
Study NCT05180461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: matching placebo of emodepside
Description: emodepside matching placebo tablet
Study NCT05180461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivermectin
Description: ivermectin tablet (overencapsulated for blinding)
Study NCT05180461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: matching placebo of ivermectin
Description: matching placebo of overencapsulated ivermectin tablet
Study NCT04705259 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Antimicrobial Stewardship ENGAGEMENT bundle
Description: Given that a single intervention is unlikely to be effective in stewardship programs, nor in care improvement processes at RACFs \[7\], this trial will deliver a set of multimodal, multidisciplinary interventions to optimise antibiotic use in RACFs. This RACF AMS ENGAGEMENT bundle will comprise the following key interventions:~* Education and engagement of prescribers, nurses, pharmacists and residents and family members~* Nursing initiatives to improve UTI diagnosis and reduce inappropriate urine testing~* Guideline development specific to antibiotic use in RACF residents~* Antimicrobial stewardship team creation in RACF with GP involvement~* EMergency department liaison and use of clinical pathways to ensure consistency of practice across the care continuum~* ElectroNic decision support to guide RACF urine testing and GP antibiotic prescribing~* Telehealth support for key intervention components
Study NCT04930562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN101
Description: BN101 is an orally ROCK2 selective inhibitor
Study NCT06509880 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Adenorine
Description: The immunostimulating effect of the drug is associated with its ability to activate the cells of the monocyte-macrophage system, thus increasing the functional activity of all parts of the body, stimulating the repair and regeneration of cells and tissues. It reduces the symptoms of the iflammatory process, stimulates the development of granulations and growth of epithelial tissues, accelerates the process of cleansing and healing of infected wounds. While with healthy people, it can be used as a phylactic drug that improves immunity protection. It was proved that when the drug is used externally, activation of macrophages occurs, thus accelerating wound cleansing process and stimulating reparative processes. In cases when thermal injury to the skin is more than 15-20% of the surface, there is a stress syndrome that suppresses the immune system. When exposed to DNA-Na, lymphocyte activation occurs, wound cleansing processes are accelerated.
Study NCT06509880 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04909099 — intervention group
Intervention type: OTHER
Intervention: Standard treatment
Description: Participants shall fill the EARS-Ar questionnaire three times within one month in addition to other questionnaires including the Roland Morris Disability Questionnaire (RMDQ) for low back pain (LBP) patients, and the Knee injury and Osteoarthritis Outcome Score (KOOS) for knee OA patients, in addition to the Fear-Avoidance Beliefs Questionnaire (FABQ), the Numeric Pain Rating Scale (NPRS), and the Global Rating of Change Scale (GRoC).~The first time will be one week after enrolling in the study and receiving the prescribed home exercise program. the second time will be 3-6 days later to test the reliability of the EARS-Ar. After another week, participants will refill the EARS-Ar and the GRoC to test responsiveness.
Study NCT05512598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0034
Description: HB0034, a single dose
Study NCT05167162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: State-Trait Anxiety Questionnaire
Description: The scale measures ordinally (1 to 5) the values observed during exposure to anxiety patterns during exercise, such as higher repetitions, greater weight gain or longer exercise duration, as follows:~1. Not at all~2. Little~3. Sometimes~4. Almost always~5. Always
Study NCT06509880 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: FOLFOX regimen
Description: (Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity > grade 1 during the first two cycles), days 3-14: Rest days)
Study NCT06509880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: (Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity > grade 1 during the first two cycles), days 3-14: Rest days)
Study NCT05167162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rating of Perceived Exertion
Description: The scale measures in ordinal form (1 to 6) the perceived effort during the exercise as follows:~1. No pain~2. Little pain~3. Moderate~4. Severe~5. Very strong~6. Unbearable
Study NCT05066360 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serum antimullerian hormone
Description: serum antimullerian hormone will be analyzed for all participants
Study NCT05446558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis
Description: Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.~Device:~Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
Study NCT05446558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal anastomosis
Description: A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.~Device:~Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
Study NCT05167162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Motor coordination tests
Description: The motor coordination tests are divided into three:~1. Jumping with 2 feet together.~2. Throwing 2 balls from a given distance and space.~3. Proprioception turns
Study NCT05167162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic intervention
Description: Participants received one session per week, until a total of 20 sessions were completed: Group 1 (n=20) received the muscle compression treatment. Group 2 (n=20) received the manual massage treatment. Group 3 (n=20) received the hydrotherapy treatment and group 4 (n=20) received the active recovery treatment.
Study NCT06350981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: 20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine
Study NCT06350981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection 30mL
Study NCT04708704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Erythrosine, prepared in drinking water (0.69 mg/kg bw/day)
Description: Erythrosine will be obtained from Roxy \& Rich Inc. (Intense Water-Soluble Food Colorant - Pink), which is certified to be edible and complies with US FDA, Health Canada, and European food safety standards. The erythrosine will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.69 mg/kg bw.
Study NCT04708704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SODIS-treated erythrosine, prepared in drinking water (0.69 mg/kg bw/day)
Description: Erythrosine will be SODIS-treated to produce photobleached erythrosine. Transparent 500 mL polyethylene terephthalate (PET) plastic water bottles will be commercially purchased (Kirkland Signature Purified Water). All branding information and labeling will be removed from the bottles. Water bottles will be dosed with \~41 mg erythrosine (0.69 mg/kg bw) using an erythrosine stock solution (8.2 g/L) and will be shaken to mix. The erythrosine-dosed bottles will be placed on a metal shelf and exposed to natural sunlight on the roof of Yale Engineering. Sunlight exposure will be conducted until the absorbance value of erythrosine at the absorption maximum of 526 nm falls below 0.05 above baseline, as measured by ultraviolet-visible spectroscopy. The water bottles containing photobleached erythrosine will be stored under refrigeration in the dark until consumption by participants.
Study NCT04708704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine, prepared in drinking water 0.075 mg/kg bw/day)
Description: Iodine used in the study will be in the form of FCC-grade potassium iodide, which will be obtained from VWR. FCC grade potassium iodide meets the requirements set by the Food Chemical Codex and is suitable for all applications in foods and beverages. Iodine (control exposure) will be prepared in 500 mL of drinking water and participants will received single daily doses for 14 days. We will use a targeted dose of 0.75 mg/kg bw.
Study NCT05719428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DRUID AI Program
Description: Patients will begin single agent therapy within 4 weeks of enrolment and continue until disease progression, maximum safe cumulative dose reached (where applicable, per standard institution practice) or unacceptable toxicity as per physician's discretion.
Study NCT05574439 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TCOC treatment
Description: The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
Study NCT05574439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TCOC treatment
Description: The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
Study NCT05574439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3 mg/ml
Description: Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
Study NCT05574439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide 3 mg/ml)
Description: Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
Study NCT05013359 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study NCT05468866 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping of rs1980422-related single-nucleotide polymorphisms by real time PCR
Description: detection of rs1980422-related single-nucleotide polymorphisms and percentage of (CD3,CD4,CD28) by immunophenotyping
Study NCT05706441 — intervention group
Intervention type: OTHER
Intervention: Point-of-Care Ultrasound
Description: Ultrasonographic scans of the lung and right hemidiaphragm were acquired after 30 min from the beginning of the SBT, or immediately before reconnecting the patient to the ventilator in the case of SBT failure occurring before
Study NCT04584437 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Infrared Energy and Dietary Supplement
Description: Infrared Energy with a wavelength of 5 - 20 microns. Multivitamins and minerals including Vitamin C Supplements.
Study NCT06230445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UHealth digital therapeutic
Description: UHealth digital therapeutic is an application that patients can report their symptoms. If the contents that patients fill in reach the threshold, UHealth application will automatic report to doctor and the doctor will give medical advisement through UHealth digital therapeutic application.
Study NCT05832203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling on planetary health diet with calorie restriction
Description: Counselling on planetary healthy diet, calorie restriction diet, and healthy lifestyle through mobile application
Study NCT05832203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Counseling on balanced nutrition diet with calorie restriction
Description: Counselling on balanced nutrition diet, calorie restriction diet, and healthy lifestyle materials through mobile app
Study NCT04975178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: MTBVAC is a novel TB vaccine candidate based on an attenuated M. tuberculosis clinical isolate of the Euro-American lineage. Attenuation is based on two independent, stable genetic deletions of the genes phoP and fadD26 coding for two major virulence factors, the transcription factor PhoP and the cell-wall lipids PDIM, respectively. We hypothesize that MTBVAC will provide improved protection, as individuals latently infected with live M.tuberculosis have an 80% lower chance of developing TB, and as MTBVAC contains most of the genes deleted from BCG and presents a wider collection of antigens to the host immune system. Preclinical studies in different animal models indicated that MTBVAC is safe and is able to induce an improved protection compared to BCG.
Study NCT04975178 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: BCG is a live attenuated M. bovis strain developed 100 years ago and is used as a preventive vaccine against tuberculosis. It is administered at birth.
Study NCT05167162 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data Analysis
Description: The usual descriptive parameters (mean and standard deviation) of the sample were calculated. The distribution and analysis of the other data were performed by means of a nonparametric test (Mann-Whitney U test) comparing the groups. A confidence level of 95% was established, considering a value of p\<0.05 as statistically significant.
Study NCT05804669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN04894
Description: CRN04894 is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
Study NCT06000865 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action video game training
Description: 20 sessions of AVG over 10 weeks (45 minutes per session, 2 sessions per week)
Study NCT06000865 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical training
Description: 20 sessions of physical training over 10 weeks (45 minutes per session, 2 sessions per week)
Study NCT05978401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-012+GLS-010
Description: Two dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
Study NCT05978401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-012+GLS-010
Description: Target dose levels will be evaluated for GLS-012+GLS-010 administered. GLS-012+GLS-010 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
Study NCT05978401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-012+GLS-010+pemetrexed+carboplatin
Description: GLS-012+GLS-010 will be given via IV infusion on Day 1 of each 21-day cycle in combination with pemetrexed and carboplatin. Combination treatment will be administered 4\~6 cycles.GLS-012+GLS-010/GLS-010 may continue until disease progression or loss of clinical benefit.
Study NCT05742646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATADORS
Description: Youth will have access to the MATADORS app to include basic information and expanded educational features. They will be asked to log into the app daily for one month and they will be asked to report within the app how they are feeling each day and their medications taken.
Study NCT05742646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MATADORS Control
Description: Youth will have access to the MATADORS app basic information. They will be asked to log into the app daily for one month and they will be asked to report within the app their medications taken.